摘要： 肝细胞癌（HCC）是最常见的恶性肿瘤之一，居癌症发病率第四位，是全球第二大癌症死亡原因。N6-甲基腺嘌呤（m⁶A）甲基化是信使RNA （mRNA）最普遍的修饰，而甲基转移酶3 （METTL3）是m⁶A RNA甲基化的核心酶。作为致癌基因，METTL3在HCC中多处于过表达状态。METTL3的过表达可增强HCC的增殖、侵袭及转移能力，降低患者的预后水平。此外，METTL3介导不同基因表达也为HCC的治疗提供诸多靶点。本文对近十年来METTL3在HCC中的研究进展进行综述，系统分析METTL3在HCC发生、治疗及预后中的作用，以期为HCC的治疗提供新的思路及方案。

甲基转移酶3在肝细胞癌中的研究进展

王朔, 柯炜炜, 卢再鸣

中国医科大学附属盛京医院放射科, 沈阳 110004

收稿日期:2022-01-16出版日期:2023-01-30发布日期:2023-02-01
通讯作者:卢再鸣E-mail:luzaiming@sina.com
作者简介:王朔（1998-），女，硕士研究生.
基金资助:国家自然科学基金（81771947）


关键词: 甲基转移酶3, N6-甲基腺苷, 肝细胞癌, 基因表达调控, 信号通路
Abstract: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. N6-methyl adenine (m⁶A) methylation is the most common modification of messenger RNA (mRNA), while methyltransferase-like 3 (METTL3) is the core enzyme of m⁶A RNA methylation. As an oncogene, METTL3 is mostly overexpressed in HCC cells; it enhances the proliferation, invasion, and metastasis of HCC cells, and reduces the prognosis and survival rate of patients. In addition, METTL3 provides several therapeutic targets for liver cancer. Therefore, in the study of tumor pathogenesis, increasing attention has been paid to the mechanism of METTL3. This paper reviews the research progress of METTL3 in HCC over the past 10 years, and systematically analyzes the role of METTL3 in the occurrence, treatment, and prognosis of HCC with the goal to provide new ideas and plans for the treatment of HCC.
Key words: methyltransferase-like 3, N6-methyl adenine, hepatocellular carcinoma, gene expression regulation, signaling pathways
PDF全文下载地址:

https://journal.cmu.edu.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=3150